A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)

Trial Profile

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Membranous glomerulonephritis; Proteinuria
  • Focus Therapeutic Use
  • Acronyms CHART
  • Sponsors Mallinckrodt Inc.; Questcor Pharmaceuticals
  • Most Recent Events

    • 30 May 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Nov 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top